Clinical Trials Logo

NHL clinical trials

View clinical trials related to NHL.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04840784 Terminated - Leukemia Clinical Trials

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Start date: June 29, 2021
Phase: Phase 1
Study type: Interventional

This Trial is a FIH, open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with R/R B-cell NHL, CLL/SLL and AML who previously received standard treatment or are ineligible for standard treatment options.

NCT ID: NCT03465540 Terminated - Multiple Myeloma Clinical Trials

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Start date: August 17, 2018
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs) and/or biologically active doses.

NCT ID: NCT02702492 Terminated - Solid Tumors Clinical Trials

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

PANAMA
Start date: June 2016
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Currently enrolling melanoma patients in combination with nivolumab, only.

NCT ID: NCT02110563 Terminated - Multiple Myeloma Clinical Trials

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Start date: April 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene MYC. MYC oncogene activation is important to the growth of many hematologic and solid tumor malignancies. In this study the Sponsor proposes to study DCR-MYC and its ability to inhibit MYC and thereby inhibit cancer cell growth.

NCT ID: NCT00814983 Terminated - MDS Clinical Trials

Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft

Start date: July 2007
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives will be to measure the safety and efficacy of allogeneic stem cell transplantation using a peripheral blood stem cell graft that has been depleted of CD45RA+ Naive T-cells. The secondary objectives will be to measure the pace of immune recovery.

NCT ID: NCT00471367 Terminated - Lymphoma Clinical Trials

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Start date: April 2007
Phase: Phase 1
Study type: Interventional

This study has two parts (A and B). The primary purpose of Part A is to find the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a twice a week basis. For Part B, an additional 20 patients will be treated at the maximum dose identified in Part A. AZD4877 is an Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth